drugset / Trial / NCT02265640
Relative Bioavailability, Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Healthy Volunteers
RandomizedCrossoverOpen-labelTreatment
Summary
The objective of the present study is to investigate the relative bioavailability of BIIL 284 BS boli in comparison to the tablet C at a dose of 75 mg in fasted condition and after a standard breakfast in healthy male volunteers
Timeline
- Start
- 2000-10
- Primary completion
- 2000-12
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AMELUBANT | Small molecule | 75 mg | — |
Indications
No indication recorded.